Furthermore combination of pertuzumab and docetaxel with agents targeting epidermal growth factor receptor and other HER family members could overcome resistance secondary to functional redundancy in the ErbB network (Reid et al, 2007) and further studies of this combination with anti-tumour activity as a primary endpoint are anticipated. The gene discussed is EGFR; the disease is neoplasm.